Morgan Stanley’s VYNE Therapeutics VYNE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$5.63K Sell
3,411
-9,400
-73% -$15.5K ﹤0.01% 7007
2025
Q1
$20.2K Buy
12,811
+8,512
+198% +$13.4K ﹤0.01% 6568
2024
Q4
$14.4K Buy
4,299
+2,500
+139% +$8.38K ﹤0.01% 6674
2024
Q3
$3.38K Hold
1,799
﹤0.01% 7013
2024
Q2
$3.54K Sell
1,799
-69
-4% -$136 ﹤0.01% 6944
2024
Q1
$5.74K Sell
1,868
-1,868
-50% -$5.74K ﹤0.01% 6857
2023
Q4
$8.7K Buy
3,736
+1,557
+71% +$3.63K ﹤0.01% 6869
2023
Q3
$8.8K Sell
2,179
-31
-1% -$125 ﹤0.01% 6777
2023
Q2
$9.06K Buy
2,210
+885
+67% +$3.63K ﹤0.01% 6844
2023
Q1
$4.08K Buy
1,325
+28
+2% +$86 ﹤0.01% 7098
2022
Q4
$3.5K Sell
1,297
-17
-1% -$46 ﹤0.01% 7243
2022
Q3
$6K Sell
1,314
-1,025
-44% -$4.68K ﹤0.01% 7220
2022
Q2
$16K Sell
2,339
-154
-6% -$1.05K ﹤0.01% 7077
2022
Q1
$29K Sell
2,493
-4,599
-65% -$53.5K ﹤0.01% 6981
2021
Q4
$131K Sell
7,092
-3,720
-34% -$68.7K ﹤0.01% 6287
2021
Q3
$271K Sell
10,812
-470
-4% -$11.8K ﹤0.01% 5839
2021
Q2
$713K Buy
11,282
+9,187
+439% +$581K ﹤0.01% 5291
2021
Q1
$258K Sell
2,095
-155
-7% -$19.1K ﹤0.01% 5506
2020
Q4
$256K Sell
2,250
-2,207
-50% -$251K ﹤0.01% 5466
2020
Q3
$533K Sell
4,457
-7,876
-64% -$942K ﹤0.01% 4613
2020
Q2
$1.54M Sell
12,333
-982
-7% -$122K ﹤0.01% 3831
2020
Q1
$2.57M Buy
13,315
+12,995
+4,061% +$2.51M ﹤0.01% 3126
2019
Q4
$106K Buy
320
+223
+230% +$73.9K ﹤0.01% 5635
2019
Q3
$31K Buy
97
+90
+1,286% +$28.8K ﹤0.01% 5889
2019
Q2
$3K Sell
7
-488
-99% -$209K ﹤0.01% 6421
2019
Q1
$280K Sell
495
-756
-60% -$428K ﹤0.01% 4883
2018
Q4
$371K Buy
1,251
+296
+31% +$87.8K ﹤0.01% 4985
2018
Q3
$677K Buy
955
+765
+403% +$542K ﹤0.01% 4811
2018
Q2
$111K Sell
190
-9
-5% -$5.26K ﹤0.01% 5715
2018
Q1
$540K Buy
+199
New +$540K ﹤0.01% 4959